Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website

Journal of Rheumatology

Volumn 40, Issue 1, 2013, Pages 34-39

  Touma, Zahi ^a   Gladman, Dafna D ^b   MacKinnon, Anne ^b   Carette, Simon ^b   Abu Shakra, Mahmoud ^c   Askanase, Anca ^d   Nived, Ola ^e   Hanly, John G ^f   Landolt Marticorena, Carolina ^b   Tam, Lai Shan ^g   Toloza, Sergio ^h   Nikpour, Mandana ⁱ   Riddell, Claire ⁱ   Steiman, Amanda ^a   Eder, Lihi ^b   Haddad, Amir ^b   Barber, Claire ^j   Urowitz, Murray B ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f DALHOUSIE UNIVERSITY   (Canada)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h Hospital San Juan Bautista ^*  (Argentina)

ⁱ ANTRIM AREA HOSPITAL   (United Kingdom)

^j UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

S2K RI 50; S2K RI 50 website; SRI 50; SRI 50 website; Systemic lupus erythematosus

Indexed keywords

ARTICLE; CLIENT SERVER APPLICATION; COMPUTER PROGRAM; DISEASE ACTIVITY; EXAMINATION; HUMAN; MEDICAL PERSONNEL; ONLINE SYSTEM; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROFESSIONAL COMPETENCE; RHEUMATOLOGY; SATISFACTION; SOCIAL PARTICIPATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOUS DISEASE ACTIVITY INDEX 2000 RESPONDER INDEX 50 WEBSITE; TRAINING; WEB BROWSER;

EID: 84871889107     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120754     Document Type: Article

References (14)

1. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. J Rheumatol 2011;38:275-84.
2. Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A reliable index for measuring improvement in disease activity. J Rheumatol 2011;38:868-73.
3. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
4. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
5. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67-70.
6. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
7. Touma Z, Gladman DD, Ibanez D, Taghavi-Zadeh S, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011;38:2395-9.
8. Touma Z, Urowitz MB, Taghavi-Zadeh S, Ibañez D, Gladman DD. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index (SRI)-50: Sensitivity at 6 and 12 months. Rheumatology 2012;51:1814-9.
9. Touma Z, Gladman DD, MacKinnon A, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index 50 (SRI-50) Manual 2010. [Internet. Accessed Sept 26, 2012.] Available from: www.sri-50.com
10. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. J Rheumatol 1999;26:504-7. (Pubitemid 29066766)
11. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902-6. (Pubitemid 41511186)
12. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
13. Touma Z, Gladman DD, Ibañez D, Urowitz MB. SLEDAI-2K Responder Index (SRI-50) captures 50% improvement in disease activity over 10 years. Lupus 2012; 21:1305-11.
14. Petri M, Pike MC, Kelley L, Kilgallen B, Gordon C. Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a phase IIb study in patients with moderate to severe systemic lupus erythematosus [abstract]. Arthritis Rheum 2011;63 Suppl:S539.